Search
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalIt was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Corticotropin
go.drugbank.com/drugs/DB01285ApprovedInvestigationalVet approvedCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Products: Acthar Gel Hp Inj 40unit/mlRiociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.
Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalTalquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … It works to recruit CD3-expressing T cells to GPRC5D-expressing multiple myeloma cells to induce T-cell–mediated cytotoxicity.
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15705ApprovedInvestigationalWithdrawnthat it was previously exposed to. … The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.
Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer FertigspritzeDosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalIt is not FDA-approved due to low therpeutic index and significant toxicity in overdose. … Its hydrochloride form is a common active ingredient in different drug formulations.
Nimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnDue to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.
Mixtures: FRENAG PLUS %1+%5 SPREY, 50 MLProducts: UL-FLAM, KITEDO-LIOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalIn patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower. … [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. … It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
Categories: Drugs Used in Diabetes